Off-Label Isotretinoin in Dermatologic Conditions: Doses, Duration, and Data

Isotretinoin, also known as 13-cis-retinoic acid, has been a mainstay in dermatologic practice since its introduction in the early 1980s. Approved by Health Canada for the treatment of severe acne vulgaris, including recalcitrant nodular acne and acne conglobata, isotretinoin has since been repurposed for a wide variety of other skin conditions. Early clinical trials using an average maximum dose of 1.2 mg/kg/day over a 16 week period demonstrated significant efficacy, with 95% of patients showing clinical improvement and 84% achieving complete clearance. Traditional isotretinoin regimens involved an initial dose of 0.5 mg/kg/day for 2–4 weeks, followed by maintenance therapy ranging from 0.1–1 mg/kg/day (up to a maximum of 2 mg/kg/day) over a total course of 12–16 weeks. However, findings from a larger dose-ranging study highlighted that side effects such as xerosis were dose-dependent, yet recurrence rates reached 42% in patients treated with 0.1 mg/kg/day, suggesting the need to carefully balance efficacy and side-effect risks when prescribing isotretinoin. More recently, micronized isotretinoin formulations and a better understanding of its pharmacodynamics have led to more widespread use of low-dose regimens. These offer similar efficacy with fewer adverse effects, better tolerability, and improved adherence.